22 février 2020 Addis-Abeba, Éthiopie
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ...de la COVID-19 par le public dans les États membres de l’Union africaine. Actuellement, il n’y a : 1. Aucune preuve scientifique provenant d’études précliniques sur l’effet thérapeutique de l’ivermectine pour le traitement de COVID-19 2. Aucune preuve de son efficacité clinique pour la prise en charge de patients présentant une COVID-19 asymptomatique, légère, modérée ou sévère 3. Aucune donnée de sécurité concernant l’utilisation de l’ivermectine pour la COVID-19 dans la majorité des études publié
more
This guidance provides considerations and a series of options that can be used to inform country strategies in managing any shortages of personal protective equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WH...O and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
16 Dec. 2020
This document provides guidance to Ministries of Health (MOHs), laboratory personnel and implementing partners in African Union Member States on the application of rapid antigen tests to COVID-19 testing. The guidance serves as reference for policymakers, laboratory leads, implementing... partners, and experts on use case scenarios and associated testing algorithms for COVID-19 antigen tests. It recommends the use of antigen tests to increase access to testing and enable timely results for persons with or without symptoms in specific settings. The document will be reviewed and updated as more evidence becomes available regarding the use of rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from global studies and evaluation efforts.
more
الاستراتيجيات لإدارة النقص الحاد في معدات الحماية الشخصية خلال جائحة فيروس COVID-19
This guidance provides considerations and a series of options that can be used to inform country strategies in managing any shortages of personal prote...ctive equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WHO and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
خيارات المرافق الخاصة
بغسل اليدين للإعدادات
محدودة الموارد
This document provides guidance to AU Member States, states/local bodies, and communities
on how to construct and maintain non-contact hand washing stations like Tippy Taps and other
al...ternative hand washing stations.
more
2-Day Orientation training Orientation Training, 1 Febr. 2021
Community Health Workers (CHWs) are an essential part of the Partnership to Accelerate COVID-19 Testing (PACT) Initiative • Africa CDC set up PACT to drive forward the Africa Union Joint Continental Strategy for COVID-19
Available in ...English, French and Arabic
more
Arabic Version of Simple instructions on how to use a face mask
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associat...ed with other medical crises ravaging the continent. A series of dedicated interventions and the introduction of innovative routes to develop drugs, involving Product Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1 HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical trials for this compound demonstrated the possibility of conducting such trials in the resource-poor settings of rural Africa.
more
La présente Stratégie pour des infrastructures sanitaires de qualité en Afrique2021-2030 (SISQA) répond à une demande des gouverneurs de la Banque africaine de développement (la BAD ou la Banque) invitant l’institution à définir son rôle dans la lutte contre les déficits d’infrastructu...res sanitaires en Afrique, en s’appuyant sur son expertise en matière de développement des infrastructures. Cette demande reconnaît que la santé joue un caractère central dans l’amélioration de la qualité de vie des Africains et l’opportunité de réaliser leur potentiel. Elle répond également à la demande croissante des pays membres régionaux (PMR), qui souhaitent que la Banque les aide à combler les lacunes en matière d’infrastructures sanitaires nationales, que la crise de la COVID-19 et d’autres crises sanitaires ont mises en évidence.
more
Cholera remains a significant public health threat in many countries worldwide. In resource-constrained settings, it disproportionately affects thousands of poor and vulnerable population